Mendelian susceptibility to mycobacterial disease (MSMD) is caused by inborn errors of interferon gamma (IFNg) immunity and is characterized by severe infections by weakly virulent mycobacteria. Although IFNg is the macrophage-activating factor, macrophages from these patients have never been studied. We demonstrate the generation of heterozygous and compound heterozygous (iMSMD-cohet) induced pluripotent stem cells (iPSCs) from a single chimeric patient, who suffered from complete autosomal recessive IFNgR1 deficiency and received bone-marrow transplantation. Loss of IFNgR1 expression had no influence on the macrophage differentiation potential of patient-specific iPSCs. In contrast, lack of IFNgR1 in iMSMD-cohet macrophages abolished IFNg-dependent phosphorylation of STAT1 and induction of IFNg-downstream targets such as IRF-1, SOCS-3, and IDO. As a consequence, iMSMD-cohet macrophages show impaired upregulation of HLA-DR and reduced intracellular killing of Bacillus Calmette-Guérin. We provide a disease-modeling platform that might be suited to investigate novel treatment options for MSMD and to gain insights into IFNg signaling in macrophages.
INTRODUCTION
Since their discovery in 2006, induced pluripotent stem cells (iPSCs) have been considered an invaluable tool for drug testing, disease modeling, and regenerative therapies (Yamanaka and Takahashi, 2006) . Nowadays, iPSCs can be generated from different sources of patient material and subsequently be differentiated into the affected cell types to study the underlying disease pathophysiology and to develop new forms of treatment. The feasibility of this approach has been highlighted for different cell types of the three germ layers. Similarly, mesodermal differentiation of iPSCs toward different cells of the hematopoietic lineage has been successfully proven . Generation of macrophages from patient-derived iPSCs is of particular interest (Lachmann et al., 2014; Mucci et al., 2016) , as these cells play an important role in tissue homeostasis and innate immunity (Ginhoux et al., 2016) . In this context, impairment of macrophage functionality due to genetic predisposition or environmental factors can lead to severe and life-threatening infections, as seen in Mendelian susceptibility to mycobacterial disease (MSMD). MSMD is a rare primary immunodeficiency characterized by clinical infections caused by weakly virulent mycobacteria in otherwise healthy individuals. Most MSMD patients suffer from severe infections triggered by Mycobacterium bovis Bacillus Calmette-Guérin (BCG), which has been used as an attenuated vaccine for tuberculosis (Bustamante et al., 2014) . Up to now, genetic defects in eight autosomal (IFNGR1, IFNGR2, STAT1, IRF8, ISG15, TYK2, IL12B, and IL12RB1) and two X-linked (CYBB and NEMO) genes, all controlling interferon gamma (IFNg) immunity, have been identified in MSMD patients (Al-Muhsen and Casanova, 2008) . Mutations in the different genes mainly affect the IFNg-signaling pathway, resulting in impaired activation of macrophages by T or natural killer (NK) cells (Bustamante et al., 2014; Chapman and Hill, 2012) .
The current form of treatment for MSMD patients consists of antibiotics in combination with IFNg therapy to restore the function of macrophages. However, patients suffering from complete autosomal recessive IFNgR1 (OMIM no.209950) or IFNgR2 (OMIM no. 614889) deficiency receive hematopoietic stem cell transplantation (HSCT) as the only curative treatment (Chantrain et al., 2006; Horwitz et al., 2003; Olbrich et al., 2015; Reuter et al., 2002; Roesler et al., 2004) . Although this therapy has been proven effective in some cases, further complications caused by the impaired functionality of macrophages, such as recurrent infections and high serum levels of IFNg, hamper the overall success of this approach. Especially the latter is of high clinical relevance, as a high serum level of IFNg directly interferes with donor hematopoietic stem cell (HSC) proliferation and consequently leads to graft rejection (Rottman et al., 2008) .
Given the limited amount of patient material available and the unsatisfactory long-term treatment alternatives for IFNgR1 or IFNgR2 deficiency, we established a diseasemodeling platform for IFNgR1 deficiency using iPSCderived macrophages. In our study, we generated patientspecific iPSCs from a small volume of peripheral blood from one patient suffering from complete autosomal recessive IFNgR1 deficiency caused by a compound heterozygous mutation in IFNgR1 who had previously received HSCT from a sibling harboring a heterozygous mutation in IFNgR1. Patient-specific macrophages, which are derived from compound heterozygous iPSCs, showed impaired IFNg-mediated signaling and functionality, thus underlining their suitability to evaluate new therapeutic interventions or to study mycobacterial infections.
RESULTS

Heterozygous and Compound Heterozygous IFNgR1-Deficient iPSC Lines Derived from a Single Chimeric MSMD Patient
In order to establish a disease-modeling platform for MSMD, we first isolated peripheral blood from a patient with MSMD due to complete autosomal recessive IFNgR1 deficiency (Roesler et al., 1999) (Figure 1A ). The patient suffered mainly from disseminated infections caused by several mycobacteria such as M. avium, M. kansasii, and BCG affecting several organs such as lymph nodes, lungs, and bones. These infections led to episodes of fever and enhanced serum parameters indicating chronic inflammation. Liver cirrhosis and meningitis caused by Listeria monocytogenes were also observed. The patient received an HSCT from her older sister with whom she shared a mutated allele (c.373+1G > T) ( Figures 1A and 1B ). This mutation is based on a G to T transition at position 1 in the 5 0 end of intron III and results in the skipping of the entire exon III, as described previously (Roesler et al., 1999) . After an initial 100% donor chimerism, the donor cells declined to roughly 50%, which was prompted by donor lymphocyte transfusions. These transfusions stabilized the chimerism at 50%-60% and the patient substantially improved clinically (Reuter et al., 2002) . After isolation of CD34 + cells from 7 mL of peripheral blood (EDTA), a ''4 in 1'' all-in-one lentiviral vector harboring the classical Yamanaka factors was used for reprogramming ( Figure 1A ). Within 10-20 days post transduction, 23 iPSC clones could be successfully established and have been subjected to further genotypic analysis. To discriminate compound heterozygous patient-specific iPSC clones from heterozygous donor cells, we performed sequencing of exon V in the IFNgR1 gene locus. The 4 bp deletion between nucleotides 561 and 564 in exon V leads to a frameshift mutation creating a premature stop codon 42 bp downstream of amino acid 187 (Roesler et al., 1999) ( Figure 1B ). Analysis of exon V revealed nine clones positive for the patient-specific 4 bp deletion at c561 (c.561del4), whereas the remaining 14 iPSC clones showed a wild-type sequence around c.561, proving their donorspecific origin ( Figure 1C ). Further genotypic analysis by semi-qPCR revealed the presence of the heterozygous mutation in the splice consensus sequence at position c.373 in exon III in all 23 iPSC clones analyzed ( Figure S1A ). After identification of donor-and patient-specific iPSCs, we established two heterozygous (iMSMD-het.4 or .9) and three compound heterozygous iPSC clones (iMSMDcohet.7, .5, or .17) for further analysis. Irrespective of their See also Figure S1 .
origin, the iMSMD-het.4 and iMSMD-cohet.7 clones showed typical iPSC morphology in bright-field images and stained positive for alkaline phosphatase activity and TRA1-60 expression, which was similar to the human embryonic stem cell line H9 ( Figure 2A ). Moreover, both MSMD lines had similar surface marker expression of SSEA4 as well as TRA1-60 and showed reactivation of endogenous OCT4, NANOG, and SOX2 expression ( Figures  2B-2D ). Pluripotency was also proven by their ability to differentiate toward cells of the three germ layers, which was analyzed by immunofluorescence staining of b3-tubulin (ectoderm), a-fetoprotein (AFP) (endoderm), and desmin (mesoderm) ( Figure 2E ). Three-lineage differentiation potential was also proven in teratoma assays.
Here, injection of iMSMD-het.4 and iMSMD-cohet.7 clones into immunocompromised NSGS mice led to the formation of cells derived from either endoderm (epithelium lining a luminal surface), mesoderm (muscle fibers or cartilage), or ectoderm (immature neuroepithelium) lineages ( Figure 2F ). Similarly, the iMSMD-het.9, iMSMD-cohet.5, and iMSMD-cohet.17 iPSC lines also fulfilled the aforementioned criteria for pluripotency ( Figures S2A-S2E ). (E) Immunofluorescent staining of iMSMD-het.4 and iMSD-cohet.7 iPSC derivatives on day 20 of undirected differentiation (first row represents staining performed for b3-tubulin, a-fetoprotein (AFP), and desmin (red); second row represents DAPI staining; and third row represents overlay images; scale bar, 100 mm).
(F) Representative H&E staining of teratoma formation after transplantation of iMSMD-het.4 (endoderm, epithelium lining a luminal surface; mesoderm, muscle fibers; or ectoderm, immature neuroepithelium) or iMSMD-cohet.7 (endoderm, epithelium lining a luminal surface; mesoderm, cartilage; or ectoderm, immature neuroepithelium) cells into immunocompromised NSGS mice (scale bar, 100 mm). See also Figure S2 .
Hematopoietic Differentiation of IFNgR1-Deficient iPSCs toward Macrophages
In order to study IFNg-mediated signaling effects in patient-or donor-specific iPSC-derived macrophages, we subjected the established iPSC lines to a previously published hematopoietic differentiation protocol . Early hematopoietic specification of iMSMDhet.4 and iMSMD-cohet.7 iPSC lines resulted in the formation of myeloid-cell-forming complexes (MCFCs) within 10 days of differentiation. From day 10-15 onward, MCFCs derived from iMSMD-het.4 and iMSMD-cohet.7 iPSCs continuously produced macrophages, which could be harvested weekly in comparable quantities. After terminal differentiation, macrophages from both sources showed typical morphology in bright-field and cytospin images compared with healthy iPSC-derived macrophages ( Figure 3A ). Of note, throughout our studies we used the previously generated and characterized iPSC control line hCD34-iPSC16 (Ackermann et al., 2014; Lachmann et al., 2014 Lachmann et al., , 2015 . Detailed characterization of (legend continued on next page) macrophages revealed a surface marker expression profile of CD11b + CD14 + CD45 + CD163 + similar to that of healthy iPSC-derived cells ( Figure 3B ). Moreover, macrophages from compound heterozygous or heterozygous iPSC clones displayed normal functional behavior with respect to phagocytosis of latex beads ( Figure 3C ). Similar observations were made when iMSMD-het.9 as well as iMSMD-cohet.5 or .17 were subjected to the macrophage generation protocol. iMSMD-derived macrophages showed typical morphology, surface marker expression profile, and the ability to phagocyte latex beads, indicating that the genetic background of our patient-specific iPSCs had no influence on the generation and differentiation potential toward macrophages ( Figures S3A-S3C ).
IFNgR1-Deficient Macrophages Show Impaired IFNg Signaling and Functionality
As a next step, we investigated the phenotypic consequence of IFNgR1 deficiency in terminally differentiated macrophages derived from healthy, iMSMD-het, or iMSMD-cohet iPSCs. Flow-cytometric analysis of IFNgR1 (CD119) revealed the absence of the receptor on macrophages derived from all iMSMD-cohet clones, whereas expression could be observed in healthy cells or macrophages harboring the heterozygous c.373+1G > T frameshift mutation only ( Figures 4A and S4A ). Of note, no change in delta mean fluorescent intensity of CD119 could be observed between macrophages derived from heterozygous iMSMD or healthy iPSCs ( Figure 4A ). In order to study the loss of IFNgR1, we next stimulated iPSC-derived macrophages with IFNg and analyzed the downstream signaling pathway. Due to the absence of IFNgR1, macrophages derived from iMSMD-cohet.7, iMSMD-cohet.5, or iMSMD-cohet.17 iPSCs were not able to phosphorylate STAT1 in the presence of IFNg. In contrast, macrophages derived from healthy, iMSMDhet.4, or iMSMD-het.9 iPSCs showed significant phosphorylation of STAT1 after stimulation with IFNg ( Figures 4B and S4B ). Of note, background phosphorylation of STAT1 could be observed in some of the experiments, which could be explained by the residual presence of and activation by M-CSF (Novak et al., 1995) ( Figure S4B ). As a consequence of defective IFNg-mediated downstream signaling, macrophages from iMSMD-cohet.7 and iMSMD-cohet.5 showed impaired upregulation of known IFNg targets such as interferon regulatory factor 1 (IRF-1), suppressor of cytokine signaling 3 (SOCS-3), or indolamin-2,3-dioxygenase (IDO). In contrast, macrophages derived from healthy or iMSMD-het.4 iPSCs were able to induce expression of IRF-1, SOCS-3, and IDO, after stimulation with IFNg ( Figures 4C and S4C) . A similar effect could be observed for the surface marker expression of MHC-class II (HLA-DR). Here, stimulation of cells with IFNg led to the upregulation of HLA-DR on healthy, iMSMD-het.4, and iMSMD-het.9 macrophages, whereas macrophages derived from either iMSMD-cohet.7, iMSMD-cohet.5, or iMSMDcohet.17 iPSCs showed no upregulation of HLA-DR after stimulation with IFNg ( Figures 4D and S4D ). As a consequence of impaired IFNg signaling, patients suffering from MSMD frequently show disseminated infections by weakly virulent mycobacteria such as non-tuberculous environmental mycobacteria or BCG vaccine. Moreover, MSMD patients are also prone to infections triggered by more virulent Mycobacterium tuberculosis, as well as non-typhoidal Salmonella spp. Thus, as a final assessment of IFNg-mediated functionality, we studied the ability of iPSC-derived macrophages to intracellularly clear BCG. To this end, we challenged our iPSC-derived macrophages with BCG in the presence of IFNg and compared the intracellular killing of iMSMD-het and iMSMD-cohet macrophages with macrophages derived from healthy hCD34-iPSC16 or macrophages derived from peripheral blood mononuclear cells (PBMCs). As expected, macrophages derived from iMSMD-cohet iPSCs showed only 20% intracellular killing activity of BCG, whereas healthy macrophages derived either from PBMC, hCD34-iPSC16, (B) Analysis of STAT1 phosphorylation (pSTAT1) in macrophage subsets stimulated with IFNg. Left image shows western blot analysis of pSTAT1 (approx. 90 kDa) in iMSMD-and hCD34-iPSC16-derived macrophages (tubulin [50 kDa] served as a control). Right image shows densitometry of pSTAT1 relative to unstimulated control (n = 5 independent experiments; mean ± SEM; **p < 0.01 by one-way ANOVA).
(C) qRT-PCR of IRF-1 (first row), SOCS-3 (second row), and IDO (third row) in iMSMD-and hCD34-iPSC16-derived macrophages after stimulation with IFNg. Values are normalized to GAPDH as a housekeeping gene (n = 3 independent experiments; mean ± SEM; *p < 0.05 by unpaired, two-tailed Students' t test; n.s., not significant).
(D) Flow-cytometric analysis of MHC-II (HLA-DR) surface marker expression by flow cytometry on iMSMD-and hCD34-iPSC16-derived macrophages before (ÀIFNg) and after stimulation (+IFNg) with IFNg (gray filled line, isotype; green line, non-stimulated control; blue line, IFNg stimulated).
(E) Intracellular killing of Bacillus Calmette-Guérin (BCG) in iMSMD-and hCD34-iPSC16-derived macrophages. PBMC-derived macrophages were used as additional control. Intracellular killing of BCG is given as a percentage, calculated to the initial time point analyzed (1-24 hr time point). The ability of mycobacterial killing was evaluated by plating a macrophage cell suspension on Middlebrook 7H10 agar plates (n = 4 independent experiments, iMSMD-het (.4 and .9); iMSMD-cohet (.7 and .17); mean ± SEM; **p < 0.01, ***p < 0.001 by one-way ANOVA). See also Figure S4 .
or iMSMD-het could clear around 85%, 80%, and 70% of intracellular BCG, respectively ( Figure 4E ).
DISCUSSION
In the present study, we established an iPSC-based diseasemodeling platform for MSMD, which is based on an autosomal recessive, complete IFNgR1 deficiency. This is of high clinical relevance as current forms of treatment for patients suffering from either IFNgR1 or IFNgR2 deficiency are limited (Chantrain et al., 2006; Horwitz et al., 2003; Olbrich et al., 2015) . Moreover, this study has also profound biological relevance, as the impact of IFNgR1 deficiency had never been studied in the main target cell of IFNg, namely macrophages. Indeed, IFNg is first and foremost a macrophage-activating-factor. Thus, we established patient-specific iPSCs from a single MSMD patient, who previously received HSCT from a healthy family member carrying a heterozygous mutation in IFNgR1 (Reuter et al., 2002; Roesler et al., 1999) . Lentiviral vectorbased reprogramming resulted in iPSC colonies within 15-20 days post transduction. Genotypic screening of iPSC clones revealed a colony subset of 40%, which were derived from compound heterozygous patient cells. This observation is similar to the patient's blood chimerism of approx. 50% at the time of reprogramming, demonstrating that loss of IFNgR1 had no detrimental effects on the reprogramming process. Of note, IFNg has been proven to directly interfere with long-term repopulating HSCs and to induce proliferation in these cells (Baldridge et al., 2010; Rottman et al., 2008) . While we enriched CD34 + cells for reprogramming, it remains to be elucidated whether the discrepancy of 10% in the patient blood chimera is of biological relevance in our system. After establishing donor-and patient-specific iPSCs, we subjected the different clones to a hematopoietic differentiation protocol to generate macrophages. Here, irrespective of their genetic background, generation and IFNg independent functionalities of iPSC-derived macrophages revealed no abnormalities. In contrast, stimulation of iMSMD-cohet macrophages with IFNg revealed deregulated STAT1 downstream signaling, which was associated with impaired breakdown of mycobacteria. Especially the latter is of high interest, as MSMD patients suffer from severe and/or recurrent infections. In our study, we used BCG, a live attenuated strain of M. bovis, which is used as a vaccine against M. tuberculosis (Colditz et al., 1994) . While BCG and other environmental mycobacteria are the most common pathogens in the context of IFNgR1 deficiency, MSMD patients are also vulnerable to other pathogens such as M. tuberculosis, Salmonella spp., or Listeria monocytogenes (Al-Muhsen and Casanova, 2008; Bustamante et al., 2014) . Whether or not these co-infections are directly linked to the IFNgR1 defect is still questionable and could be addressed using our established disease-modeling platform. However, here more advanced differentiation systems would be favorable in order to study the complex role of IFNg in both innate and adaptive immunity. iPSC-based differentiation systems that are able to generate B, T, or NK cells French et al., 2015; Sturgeon et al., 2014) may be employed and could be combined with iPSC-derived macrophages to study the crosstalk between different immune cells in an autologous setting. Using this approach, other MSMD-causing mutations could also be investigated. Thus, iPSC-derived macrophages could be used to gain new insights into deficiencies due to mutations in IFNgR2, STAT1, NEMO, IRF8, or CYBB, whereas iPSCderived lymphocytes could be used to study functional defects due to IL12RB1 deficiency. In addition, genome editing tools such as CRISPR/Cas9 could be used in order to correct the disease-causing mutation or to perform further loss-of-function studies on an isogenic background . This being said, targeted disruption of IRF8 by CRISPR/Cas9 genome editing in iPSCs has been used to study the development of dendritic cells (Sontag et al., 2017) . These genetically modified iPSCs and their isogenic controls could also be used to study the effect of IFNg signaling in the context of MSMD.
Taken together, we provide a disease-modeling platform for MSMD due to complete IFNgR1 deficiency. Considering the importance of IFNg signaling throughout the hematopoietic system, the established iPSC lines could be used as a screening platform to investigate new forms of treatment for MSMD. Moreover, our iPSC disease-modeling platform might also have broader applicability and may also be used to study the biology and treatment options for other mycobacterial infections, such as tuberculosis.
EXPERIMENTAL PROCEDURES
Human peripheral blood samples were collected after written informed consent of the donor at Universitätsklinikum Dresden (Germany). Ethical vote no. 2127-2014 was approved by the Institutional Ethical Committee at Hannover Medical School (Hannover, Germany).
Work related to the human ESC-line H9 was approved by the Robert Koch Institut (No: 1710-79-1-4-81).
Hematopoietic Differentiation of iPSCs toward Monocytes and Macrophages
iPSC-derived macrophages were generated using a modified version of the previously established embryoid body (EB)-based hematopoietic protocol (Lachmann et al., 2014 . iPSCs were disrupted by collagenase V and transferred into six-well suspension plates for EB formation in embryonic stem cell medium without basic fibroblast growth factor and 10 mM Rock inhibitor (Y-27632; Tocris, Bristol, UK) for 5 days on a rotator shaker (85 rpm). Thereafter, myeloid-cell-forming complex formation was performed in the presence of X-Vivo15 medium (Lonza, Hessisch Oldendorf, Germany) supplemented with 2 mM L-glutamine, 1% penicillin/ streptomycin (PS), 50 ng/mL human macrophage colony stimulating factor (hM-CSF), and 25 ng/mL human interleukin 3 (Preprotech). The macrophages generated were harvested once a week and filtered through a 100 mM mesh. Harvested cells were cultured in RPMI1640 supplemented with 10% fetal calf serum, 2 mM L-glutamine, 1% PS, and 50 ng/mL hM-CSF.
Additional experimental procedures are provided in Supplemental Experimental Procedures.
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